drugset / Trial / NCT01553032

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)

NCT01553032

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a national multicenter phase IV study to assess acute radiation dermatitis of combined radioimmuno(chemo)therapy with Cetuximab in patients with locally advanced, non-metastatic squamous cell carcinoma of the head and neck (LASCCHN).

Timeline

Start
2011-06
Primary completion
2017-05
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cetuximab Monoclonal antibody 250 mg/m2

Indications